For instance, thalidomide, an inhibitor of TNF-α, reduced serum proinflammatory cytokine concentrations, lowered motor neuron death and improved motor function in an ALS mouse model; however, it did not meet clinical endpoints in a phase 2 clinical trial in a small cohort of ALS patients [207]. This evidence concerns the gene TNF and amyotrophic lateral sclerosis.